Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600671's EV-to-EBITDA is ranked worse than 97.38% of 726
companies
in the Drug Manufacturers industry
Industry Median: 13.63
vs SHSE:600671: 150.04
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hangzhou TianMuShan Pharmaceutical Enterprise Co's PE Ratio (TTM) for today is calculated as:
Hangzhou TianMuShan Pharmaceutical Enterprise Co's share price for today is ¥21.88.
Hangzhou TianMuShan Pharmaceutical Enterprise Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.113.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou TianMuShan Pharmaceutical Enterprise Co EV-to-EBITDA Chart
Hangzhou TianMuShan Pharmaceutical Enterprise Co Annual Data
SHSE:600671 vs LLY, JNJ, ABBV: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Hangzhou TianMuShan Pharmaceutical Enterprise Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou TianMuShan Pharmaceutical Enterprise Co EV-to-EBITDA vs Drug Manufacturers Industry
Hangzhou TianMuShan Pharmaceutical Enterprise Co's current Enterprise Value is ¥2,806.8 Mil.
Hangzhou TianMuShan Pharmaceutical Enterprise Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥18.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671) has a EV-to-EBITDA of 150.04 as of Sep. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Hangzhou TianMuShan Pharmaceutical Enterprise Co. This is 566% above median its historical median of 22.52. According to the industry distribution chart, Hangzhou TianMuShan Pharmaceutical Enterprise Co ranks #707 out of 726 companies in the Drug Manufacturers industry, placing it in the top 97.4%.
Is Hangzhou TianMuShan Pharmaceutical Enterprise Co's EV-to-EBITDA too high?
Hangzhou TianMuShan Pharmaceutical Enterprise Co's current EV-to-EBITDA of 150.04 is 566% above median its 10-year median of 22.52. The Drug Manufacturers industry median EV-to-EBITDA is 13.63. Hangzhou TianMuShan Pharmaceutical Enterprise Co's value of 150.04 is 1000.8% above this industry median. Based on the distribution chart, Hangzhou TianMuShan Pharmaceutical Enterprise Co ranks #707 out of 726 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Hangzhou TianMuShan Pharmaceutical Enterprise Co has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou TianMuShan Pharmaceutical Enterprise Co's EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Hangzhou TianMuShan Pharmaceutical Enterprise Co ranks #707 out of 726 companies for EV-to-EBITDA. This places Hangzhou TianMuShan Pharmaceutical Enterprise Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.63. Hangzhou TianMuShan Pharmaceutical Enterprise Co's value of 150.04 is 1000.8% above this benchmark. While the company's 10-year median is 22.52 vs. the industry median of 13.63, Hangzhou TianMuShan Pharmaceutical Enterprise Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.63, based on 726 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou TianMuShan Pharmaceutical Enterprise Co's current EV-to-EBITDA of 150.04 is 1000.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Hangzhou TianMuShan Pharmaceutical Enterprise Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou TianMuShan Pharmaceutical Enterprise Co's current EV-to-EBITDA is 150.04, which is 566% above median its own 10-year median of 22.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou TianMuShan Pharmaceutical Enterprise Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥15.03, compared to a current price of ¥21.88 — trading 45.6% above its estimated fair value. The current EV-to-EBITDA is 150.04, which is 566% above median its 10-year median of 22.52 and 1000.8% above the Drug Manufacturers industry median of 13.63. Hangzhou TianMuShan Pharmaceutical Enterprise Co's overall GF Score™ is 47/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671), the current EV-to-EBITDA is 150.04 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou TianMuShan Pharmaceutical Enterprise Co stock appears to be overvalued.
The current stock price of ¥21.88 is trading 45.6% above its estimated GF Value™ of ¥15.03.
GuruFocus considers Hangzhou TianMuShan Pharmaceutical Enterprise Co to be Significantly Overvalued.
Key valuation signals for SHSE:600671:
EV-to-EBITDA: 150.04 (566% above median its 10-year median of 22.52)
GF Value™: ¥15.03 vs. price of ¥21.88 (45.6% above fair value)
Industry Position: 1000.8% above the Drug Manufacturers median (#707 of 726)
No single metric tells the full story. See the SHSE:600671 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd is engaged in producing proprietary Chinese medicines, biopharmaceuticals, healthy foods, medical equipment, and other medicines in China.
47GF Score
Get the complete analysis for SHSE:600671
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600671 has been successfully added to your 
